Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
White Paper
Synthetic Control Arms: Considerations Around Definition, Drivers, and Design
Those that work in the biopharmaceutical or device industry are likely familiar with the term synthetic controls. But what exactly are synthetic…
View Resource
Blog
Bridging Recruitment Gaps with Academic Collaboration
Read Story
Webcast
THE INSIGHT SERIES: Introduction to Myths and Misconceptions of Late Phase – Part 1
Late phase research has changed substantially over the past decade. During this period of innovation and development, many myths and misconceptions…
View Resource
View all related content and resources for Real world solutions
Explore Insights